MAP2K7 and embryonal rhabdomyosarcoma: Given the good tolerance of MEK inhibitory treatment, therapy with trametinib is ongoing, and the girl is constantly showing developmental progress and no signs of cancer relapse 29 months after the initial diagnosis of embryonal rhabdomyosarcoma.